PRIMARY DOCUMENT

Company

PUMA BIOTECHNOLOGY, INC.

Filed

June 29, 2020

Accession Number

0001654954-20-007101

A Schedule 13G is filed when a passive investor acquires more than 5% of a company's shares without intent to influence control. Learn more about SC 13G filings →